

7. Literaturverzeichnis

1. Abbasoglu O, Levy MF, Brkic BB, Testa G, Jeyarajah DR, Goldstein RM, Husberg BS, Gonwa TA, Klintmalm GB (1997).
Ten years of liver transplantation: an evolving understanding of late graft loss.
Transplantation; 64(12): 1801-1807.
2. Abbasoglu O, Levy MF, Vodapally MS, Goldstein RM, Husberg BS, Gonwa TA, Klintmalm GB (1997).
Hepatic artery stenosis after liver transplantation--incidence, presentation, treatment, and long term outcome.
Transplantation; 63(2): 250-255.
3. Adam R, McMaster P, O'Grady JG, Castaing D, Klempnauer JL, Jamieson N, Neuhaus P, Lerut J, Salizzoni M, Pollard S, Muhlbacher F, Rogiers X, Garcia Valdecasas JC, Berenguer J, Jaeck D, Moreno Gonzalez E; European Liver Transplant Association. (2003)
Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry.
Liver Transpl; 9(12):1231-1243.
4. Adams PC, Ghent CN, Grant DR, Wall WJ (1995).
Employment after liver transplantation.
Hepatology; 21(1): 140-144.
5. Allison AC, Eugui EM (2000).
Mycophenolate mofetil and its mechanisms of action. Review.
Immunopharmacology; 47: 85-118.
6. Altman DG (1997).
Practical statistics for medical research.
Chapman & Hall; London
7. Armenti VT, Herrine SK, Radomski SK, Moritz MJ (2000).
Pregnancy after liver transplantation.
Liver Transpl; 6(6): 671-685.
8. Armenti VT, Radomski JS, Moritz MJ, Philips LZ, McGrory CH, Coscia LA (2000).
Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation.
Clin Transpl: 123-134.
9. Arnow PM, Carandang GC, Zabner R, Irwin ME (1996).
Randomized controlled trial of selective bowel decontamination for prevention of infections following liver transplantation.
Clin Infect Dis; 22: 997-1003.
10. Asfar S, Metrakos P, Fryer J, Verran D, Ghent C, Grant D, Bloch M, Burns P, Wall W (1996).
An analysis of late deaths after liver transplantation.
Transplantation; 61(9): 1377-1381.
11. Aw MM, Samaroo B, Baker AJ, Verma A, Rela M, Heaton ND, Mieli-Vergani G, Dhawan A (2001).
Calcineurin-inhibitor related nephrotoxicity – reversibility in paediatric liver transplant recipients.
Transplantation; 72(4): 746-749.

12. Azoulay D, Lindhares MM, Huguet E, Delvart V, Castaing D, Adam R, Ichai P, Saliba F, Lemoine A, Samuel D, Bismuth H (2002).
Decision for retransplantation of the liver.
Ann Surg; 236: 713-721.
13. Barkmann A, Nashan B, Schmidt HHJ, Boker KH, Emmanouilidis N, Rosenau J, Bahr MJ, Tusch G, Manns MP, Klempnauer J, Schlitt HJ (2000).
Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil.
Transplantation; 69(9):1886-1890.
14. Baid S, Cosimi AB, Farrell ML, Schoenfeld DA, Feng S, Chung RT, Tolkoff-Rubin N, Pascual M (2001).
Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality.
Transplantation; 72(6): 1066-1072.
15. Bechstein WO, Riess H, Neuhaus P, Himmelreich G, Steffen R, Slama KJ, Rossaint R, Blumhardt G (1990).
The effect of aprotinin on blood product requirements during orthotopic liver transplantation.
Clin Transplant; 5: 422-426.
16. Bechstein WO, Wiens M, Raakow R, Blumhardt G, Neuhaus P (1993).
Spezielle unterstützende Therapie (Ernährung, Infektionsbekämpfung, Intensivtherapie) in der Transplantationstherapie.
Zentralbl Chir; 118: 477-481.
17. Bechstein WO, Blumhardt G, Lobeck H, Keck H, Lemmens HP, Knoop M, Neuhaus P (1994).
Selection of small hepatocellular Karzinoma improves long-term results of hepatic transplantation for malignancy.
Transplant Int; 7 (Suppl): 238-240.
18. Bechstein WO, Guckelberger O, Kling N, Rayes N, Tullius SG, Lobeck H, Vogl T, Jonas S, Neuhaus P (1998).
Recurrence-free survival after liver transplantation for small hepatocellular Karzinoma.
Transplant Int; 11 (Suppl 1): S78-81.
19. Bechstein WO, Neuhaus P (2000).
Bleeding problems in liver surgery and liver transplantation. Review.
Chirurg 71(4): 363-368.
20. Becker T, Nyibata M, Lueck R, Bektas H, Demirci G, Lehner F, Tusch G, Strassburg C, Schwarz A, Klempnauer J, Nashan B (2003).
Results of combined and sequential liver-kidney transplantation.
Liver Transpl; 9(19): 1067-1078.
21. Belle SH, Porayko MK, Hoofnagle JH, Lake JR, Zetterman RK (1997).
Changes in quality of life after liver transplantation among adults.
Liver Transpl Surg; 3: 93-104.
22. Ben-Ari Z, Pappo O, Mor E (2003).
Intrahepatic cholestasis after liver transplantation.
Liver Transpl; 9 (10): 1005-1018.
23. Benichou J, Halgrimson CG, Weil R, Koep LJ, Starzl TE (1977).
Canine and human liver preservation for 6 to 18 hr by cold infusion.
Transplantation; 24(6): 407-411.

24. Beresford TP (2001).
Neuropsychiatric complications of liver and other solid organ transplantation.
Liver Transpl;7(11 Suppl 1): S36-S45. Review
25. Berg T, Hopf U, Bechstein WO, Müller AR, Fukumoto T, Neuhaus R, Lobeck H, Neuhaus P (1998).
Pretransplant virological markers hepatitis C virus genotype and viremia level are not helpful to predict the individual outcome after orthotopic liver transplantation.
Transplantation; 66(2): 225-228.
26. Bergquist A, Ekblom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, Hultcrantz R, Lindgren S, Prytz H, Sandberg-Gertzen H, Almer S, Granath F, Broome U (2002).
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.
J Hepatol; 36: 321-327.
27. Berenguer M (2002).
Natural history of recurrent hepatitis C.
Liver Transpl; 8(10), Suppl. 1: S14-S18.
28. Berlakovich GA, Langer F, Freundorfer E, Windhager T, Rockenschaub S, Sporn E, Soliman T, Pokorny H, Steininger R, Muhlbacher F (2000).
General compliance after liver transplantation for alcoholic cirrhosis.
Transpl Int; 13(2): 129-135.
29. Biggins SW, Beldecos A, Rabkin JM, Rosen HR (2002).
Retransplantation for hepatic allograft failure: Prognostic modeling and ethical considerations.
Liver Transplant; 8(4): 313-322.
30. Bilbao I, Charco R, Hidalgo E, Lazaro JL, Balsells J, Murio E, Margarit C (1997).
Risk factors for severe ischemic injury after liver transplantation.
Transplant Proc; 29(1-2): 368-370.
31. Bilbao I, Armadans L, Lazaro JL, Hidalgo E, Castells L, Margarit C (2003).
Predictive factors for early mortality following liver transplantation.
Clin Transplant; 17: 401-411.
32. Bismuth H, Houssin D (1984).
Reduced-size orthotopic liver graft in hepatic transplantation in children.
Surgery; 95: 367-372.
33. Bismuth H, Morino M, Castaing D, Gillon MC, Descorps-Declere A, Saliba F, Samuel D (1989).
Emergency orthotopic liver transplantation in two patients using one donor liver.
Br J Surg; 76: 722-724.
34. Bismuth H, Majno PE, Adam R (1999).
Liver transplantation for hepatocellular carcinoma.
Semin Liver Dis; 19: 311-322.
35. Blanco JJ, Herrero JJ, Quiroga J, Sangro B, Gómez-Manero N, Pardo F, Cienfuegos JA, Prieto J (2001).
Liver transplantation in cirrhotic patients with diabetes mellitus: midterm results, survival, and adverse events.
Liver Transpl; 7(3): 226-233.

36. Blum HE, Hopt UT (2003).
Hepatozelluläres Karzinom. Pathogenese und das Problem der Multizentrität.
Chirurg; 74: 709-716.
37. Blumhardt G, Lemmens P, Topalidis T, Meissler M, Baer P, Steffen R, Schön M, Müller C, Neuhaus P (1993).
Increased flow rate of preservation solution in the hepatic artery during organ preservation can improve postischemic liver function.
Transplant Proc; 25: 2540-2542.
38. Bonsel GJ, Essink-Bot ML, Klompmaker IJ, Slooff MJ (1992).
Assessment of the quality of life before and following liver transplantation. First results.
Transplantation; 53(4):796-800.
39. Bravata DM, Olkin I, Barnato AE, Keeffe EB, Owens DK (1999).
Health-related quality of life after liver transplantation: a meta analysis.
Liver Transpl Surg; 5(4): 318-331.
40. Bravata DM, Keeffe EB (2001).
Quality of life and employment after liver transplantation.
Liver Transpl; 7(11), Suppl 1: S119-S123.
41. Bravata DM, Olkin I, Barnato AE, Keeffe EB, Owens DK (2001).
Employment and alcohol use after liver transplantation for alcoholic and nonalcoholic disease: a systematic review.
Liver Transpl; 7(3): 191-203.
42. Brent LB (1997).
A History of Transplantation Immunology.
Academic Press 1997.
43. Brent LB, Calne RY, Dausset JB, Good RA, Murray JE, Schwartz RS, Shumway NE, Starzl TE, Teresaki PI, Thomas ED, van Rood JJ (2000).
Historical landmarks in clinical transplantation.
World J Surg; 24: 755-843.
44. Broelsch CE, Emond JC, Whittington PF, Thistlethwaite Baker AL, Lichtor JL (1990).
Application of reduced-size liver transplants as split grafts, auxiliary orthotopic grafts, and living related segmental transplants.
Ann Surg; 212: 368-377.
45. Broelsch CE, Malagó M, Testa G, Gamazo CV (2000).
Living donor liver transplantation in adults: outcome in Europe.
Liver Transpl; 6: S64-65.
46. Broelsch CE, Frilling A, Nadalin S, Valentin GC, Kühl H, Gerken G, Malago M (2003).
Leberlebenspende. Die deutsche Erfahrung im internationalen Vergleich.
Chirurg; 74: 510-522.
47. Brokelman W, Stel AL, Ploeg RJ (1999).
Risk factors for primary dysfunction after liver transplantation in the University of Wisconsin solution era.
Transplant Proc; 31(5): 2087-2090.

48. Bronster DJ, Emre S, Boccagni P, Sheiner PA, Schwartz ME, Miller CM (2000).
Central nervous system complications in liver transplant recipients--incidence, timing, and long-term follow-up.
Clin Transplant;14(1):1-7.
49. Bryan R, Ratcliffe J, Neuberger JM, Burroughs AK, Gunson BK, Buxton MJ (1998).
Health-related quality of life following liver transplantation.
Qual Lif Res; 7: 115-120.
50. Büsing M, Köveker G, Hopt UT, Greger B, Becker HD (1994).
Standardisierung der kombinierten Pankreas- und Leberexplantation.
Chirurg; 65: 1130-1135.
51. Burkhalter EL, Starzl TE, Van Thiel DH (1994).
Severe neurological complications following orthotopic liver transplantation in patients receiving FK 506 and prednisone.
J Hepatol; 21(4): 572-577.
52. Bussutil RW, Klintmalm GB (1996).
Transplantation of the liver. 1st ed..
WB Saunders Company; Philadelphia – London – Toronto – Montreal – Sydney – Tokyo.
53. Buti M, Mas A, Prieto M, Buti M, Mas A, Prieto M, Casafont F, Gonzalez A, Miras M, Herrero JI, Jardi R, Cruz de Castro E, Garcia-Rey C (2003).
A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation.
J Hepatol; 38: 811-817.
54. Butt AK, Khan AA, Alam A, Shah SWH, Shafqat F, Naqvi AB (1998).
Predicting hospital mortality in cirrhotic patients: Comparison of Child-Pugh and acute physiology , age and chronic health evaluation (APACHE III) scoring systems.
Am J Gastroenterol; 93 (12): 2469-2475.
55. Cai TH, Esterl Jr RM, Nichols L, Cigarroa F, Speeg KV, Halff GA (1998).
Improved Immunosuppression with combination Tacrolimus (FK 506) and Mycophenolat Acid in orthotopic liver transplantation.
Transplant Proc;30: 1413-1414.
56. Calne RY, Williams R (1968).
Liver transplantation in man – I, Observation on technique and organization in five cases.
Br Med J; 4: 535-540.
57. Calne RY, Rolles K, White DJD, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Henderson RG, Aziz S, Lewis P (1979).
Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases and 2 livers.
Lancet; 2: 1033-1036.
58. Calne RY, Williams R, Lindop M, Farman JV, Tolley ME, Rolles K, MacDougall B, Neuberger J, Wyke RJ, Raftery AT, Duffy TJ, Wight DG, White DJ (1981).
Improved survival after orthotopic liver grafting.
Br Med J; 283: 115-118.

59. Calne RY (1982).
The initial study of the immunosuppressive effects of 6-mercaptopurine and azathioprine in organ transplantation and a few words on cyclosporin A.
World J Surg; 6(5): 637-640.
60. Canalis E, Delany AM (2002).
Mechanisms of glucocorticoid action in bone.
Annals of the New York Academy of Sciences; 966: 73-81.
61. Cannon JA (1956).
Brief report.
Transplant Bull; 3: 7.
62. Canzanello VJ, Schwartz L, Taler SJ, Textor SC, Wiesner RH, Porayko MK, Krom RA (1997).
Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506).
Liver Transpl Surg; 3(1): 1-9.
63. Carden DL, Granger DN (2000).
Pathophysiology of ischemia-reperfusion injury.
J Pathol; 190(3): 255-266.
64. Carey WD, Dumot JA, Pimentel RR, Barnes DS, Hobbs RE, Henderson JM, Vogt DP, Mayes JT, Westveer MK, Easyley KA (1995).
The prevalence of coronary artery disease in liver transplant candidates over age 50.
Transplantation; 59(6): 859-864.
65. Carithers RL Jr (2000).
Liver transplantation.
Liver Transpl; 6: 122-135.
66. Carr-Hill RA, Kind P (1989).
The Nottingham Health Profile.
Soc Sci Med; 28(8):885.
67. Carson KL, Hunt CM (1997).
Medical problems occurring after orthotopic liver transplantation.
Dig Dis Sci; 42(8): 1666-1674.
68. Casavilla FA, Marsh JW, Iwatsuki S (1997).
Hepatic resection and transplantation for peripheral cholangiocarcinoma.
J Am Coll Surg; 185: 429-436.
69. Casele HL, Laifer SA (1998).
Association of pregnancy complications and choice of immunosuppressant in liver transplant patients.
Transplantation; 65(4): 581-583.
70. Cavallari A, Vivarelli M, Belusci R, Jovine E, Mazziotti A, Rossi C (2001).
Treatment of vascular complications following liver transplantation: multidisciplinary approach.
Hepatogastroenterology; 48(37): 179-183.
71. Charlton M (2002).
Pre-emptive treatment of recurrent hepatitis C infection in liver transplant recipients.
Liver Transpl; 8(10), Suppl. 1: S50-S54.

72. Chatzipetrou MA, Tsaroucha AK, Weppeler D, Pappas PA, Kenyon NS, Nery JR, Khan MF, Kato T, Pinna AD, O'Brien C, Viciano A, Ricordi C, Tzakis AG (1999).
Thrombocytopenia after liver transplantation.
Transplantation; 67(5):702-706.
73. Child CG, Turcotte JG (1964).
Surgery and portal hypertension.
In: Child CG (Hrsg.): The liver and the portal hypertension.
Philadelphia; Saunders: 50-78.
74. Coelho JC, Parolin MB, Matias JE (2002).
Successful twin pregnancy after orthotopic liver transplantation
Arq Gastroenterol; 39(4): 246-247.
75. Cofer JB, Klintmalm GB, Howard TK, Morris CV, Husberg BS, Goldstein RM, Gonwa TA (1990).
A comparison of UW with Eurocollins preservation solution in liver transplantation.
Transplantation; 49(6): 1088-1093.
76. Cohen AJ, Stegall MD, Rosen CB, Wiesner RH, Leung N, Kremers WK, Zein NN (2002).
Chronic renal dysfunction late after liver transplantation.
Liver Transplant; 8(10): 916-921.
77. Collins GM, Dubernard JM, Persijn GG, Land W (Hrsg.) (1995).
Procurement and Preservation of Vascularized Organs.
Kluwer Acadec Publ., Dordrecht 1995
78. Colonna JO, Brems JJ, Golstein LI, Millis JM, Vargas JH, Berquist WE, Ray RA, Lewin KJ, Brill JE (1988).
The importance of percutaneous liver biopsy in the management of liver transplant recipient.
Transplant Proc; 1: 682-684.
79. Compston JE (2003).
Osteoporosis after liver transplantation.
Liver Transpl. 2003 Apr;9(4): 321-30. Review.
80. Consensus Conference on indications of liver transplantation (1984).
Hepatology; 20: 63-68.
81. Cooper D, Russell J, Chitman KD, Williams MC, Wolf RE, Granger DN (2004).
Leukocyte dependence of platelet adhesion in postcapillary venules.
Am J Physiol Heart Circ Physiol; 286: 1895-1900.
82. Cosimi AB, Cho SI, Delmonico FL, Kaplan MM, Rohrer RJ, Jenkins RL (1987).
A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection.
Transplantation; 43(1): 91-95.
83. Cotterell AH, Fisher RA, King AL, Gehr TWB, Dawson S, Sterling RK, Stravitz RT, Luketic VA, Sanyal AJ, Shiffman ML, Posner MP (2002).
Calcineurin-inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent.
Clin Transplant; 16: 49-51.

84. Cowling T, Jennings LW, Goldstein RM, Sanchez EQ, Chinnakotla S, Klintmalm GB, Levy MF (2004).
Societal reintegration after liver transplantation: findings in alcohol-related and non-alcohol related transplant recipients.
Ann Surg; 239 (1): 93-98.
85. Creput C, Durrbach A, Samuel D, Eschwege P, Amor M, Kriaa F, Kreis H, Benoit G, Bismuth H, Carpentier B (2003).
Incidence of renal and liver rejection and patient survival rate following combined liver and kidney transplantation.
Am J Transplant; 3(3): 348-356.
86. Crippin JC (2001).
Bone disease after liver transplantation.
Liver Transpl; 11(Suppl.1): S27-S35.
87. Cvetkovic M, Mann GN, Romero DF (1994).
The deleterious effects of long-term cyclosporin A, cyclosporin G, and FK506 on bone mineral metabolism in vivo.
Transplantation; 57(8): 1231-1237.
88. Deltz E, Schroeder P, Gundlach M, Timmermann W, Engemann R, Leimenstoll G, Hansman ML, Westphal E, Hamelmann H (1989).
Successful clinical small bowel transplantation: Report of a case.
Clin Transplant; 3: 89-91.
89. Demetris AJ, Fung JJ, Todo S, McCauley J, Jain A, Takaya S, Alessiani M, Abu-Elmagd K, Van Thiel DH, Starzl TE (1992).
Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy - a clinicopathologic study of 96 patients.
Transplantation; 53(5): 1056-1062.
90. Desai NM, Mange KC, Crawford MD, Abt PL, Frank AM, Markmann JW, et al (2004).
Predicting outcome after liver transplantation: utility of the model for end-stage liver disease and a newly derived discrimination function.
Transplantation; 77(1): 19-21.
91. Dickson RC, Wright RM, Bacchetta MD, Bodily SE, Caldwell SH, Driscoll CJ, Pruett TL, Ishitani MB (1997).
Quality of life of hepatitis B and C patients after liver transplantation.
Clin Transplant; 11: 282-285.
92. Drazan K, Shaked A, Olthoff KM, Imagawa D, Jurim O, Kiai K, Shackelton C, Busuttil R (1996).
Etiology and management of symptomatic adult hepatic artery thrombosis after orthotopic liver transplantation (OLT).
Am Surg; 62(3): 237-240.
93. DSO - Deutsche Stiftung Organtransplantation (Hrsg.) (1998).
Gesetz über die Spende, Entnahme und Übertragung von Organen, Transplantationsgesetz. Deutsche Stiftung Organtransplantation, Neu-Isenburg, 1998. www.dso.de
94. Dumortier J, Czyglik O, Poncet G, Blanchet MC, Boucaud C, Henry L, Boillot O (2002).
Eversion thrombectomy for portal vein thrombosis during liver transplantation.
Am J Transplant; 2(10): 934-938.

95. Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O (2003).
Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results.
Am J Transplant; 3(8): 999-1002.
96. Duvoux C (2001).
De novo tumours after liver transplantation in adults. What is the actual risk?
J Hepatol; 34: 161-164.
97. Echaniz A, Pita S, Otero A, Suarez F, Gomez M, Guerrero A (2003).
Incidence, risk factors and influence on survival of infectious complications after liver transplantation.
Entferm Infec Micriobiol Clin; 21(5): 224-231.
98. Eckhoff DE, McGuire BM, Frenette LR, Contreras JL, Hudson SL, Bynon JS (1998).
Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation.
Transplantation; 65(2): 180-187.
99. Elliot JF, Lin Y, Mizel SB, Bleackley RC, Harnish DG, Paetkau V (1984).
Induction of interleukin-2 messenger RNA inhibited by cyclosporin A.
Science; 226: 1439-1441.
100. Emre S, Sebastian A, Chodoff L, Boccagni P, Meyers B, Sheiner PA, Mor E, Guy SR, Atillasoy E, Schwartz ME, Miller CM (1999).
Selective decontamination of the digestive tract helps prevent bacterial infections in the early postoperative period after liver transplant.
Mt Sinai J Med; 66(5-6): 310-313.
101. Esquivel CO, Nakazato P, Cox K, Concepcion W, Berquist W, Russel TR (1991).
The impact of liver reductions in pediatric liver transplantation.
Arch Surg; 126: 1278-1285.
102. European FK506 Multicentre Liver Study Group (1994).
Randomized trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection.
Lancet; 344: 423-427.
103. European Liver Transplant Registry – ELTR. Annual Report - www.eltr.org
104. Eypasch E, Egeler B, Troidl H (1997).
Bedeutung und Messung der Lebensqualität.
In: Fuchs KH, Stein HJ, Thiede A (Hrsg.): *Gastrointestinale Funktionsstörungen*. Berlin, Springer-Verlag: 1-23.
105. Fabrega E, Crespo J, Casafont F, De las Heras G, de la Pena J, Pons-Romero F (1998).
Alcoholic recidivism after liver transplantation for alcoholic cirrhosis.
J Clin Gastroenterol; 26(3): 204-206.
106. Fernandez JA, Robles R, Marin C, Hernandez Q, Sanchez Bueno F, Ramirez P, Rodriguez JM, Lujan JA, Navalon JC, Parrilla P (2003).
Role of liver transplantation in the management of metastatic neuroendocrine tumors.
Transplant Proc; 35(5): 1832-1833.

107. Fernandez-Miranda C, Sanz M, dela Calle A, Loinaz C, Gomez R, Jimenez C, Garcia I, Gomez de la Camara A, Moreno E (2002).
Cardiovascular risk factors in 116 patients 5 years or more after liver transplantation.
Transplant Int; 15(11): 556-562.
108. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM (1998).
Chronic renal failure following liver transplantation: a retrospective analysis.
Transplantation; 66(1): 59-66.
109. Fishman JA, Rubin RH (1998).
Infection in organ-transplant recipients.
N Engl J Med; 338: 1741-1751.
110. Fishman JA (2002).
Overview: fungal infection in the transplant patient.
Transpl Infect Dis; 4, Suppl 3: 3-11.
111. Florman S, Toure B, Kim L, Gondolesi G, Roayaie S, Krieger N, Fishbein T, Emre S, Miller C, Schwartz M (2004).
Liver transplantation for neuroendocrine tumors.
J Gastrointest Surg; 8(2):208-212.
112. Foster PF, Fabrega F, Karademir S, Sankary HN, Mital D, Williams JW (1997).
Prediction of abstinence from ethanol in alcoholic recipients following liver transplantation.
Hepatology; 25(6): 1469-1477.
113. Fraser-Smith E, Rosete J, Schatzman R (1995).
Suppression by mycophenolate mofetil of the neointimal thickening caused by vascular injury in a rat arterial stenosis model.
J Pharmacol Exp Ther; 275(3): 1204-1208.
114. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002).
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
N Engl J Med; 348: 259-260.
115. Fukumoto T, Berg T, Ku Y, Bechstein WO, Knoop M, Lemmens HP, Lobeck H, Hopf U, Neuhaus P (1996).
Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions.
Hepatology; 24: 1351-1354.
116. Fuller RK (1997)
Definition and Diagnosis of relapse of drinking.
Liver Transplant Surg; 3: 258-262.
117. Fung JF, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B (2001).
De novo malignancies after liver transplantation: a major cause of late death.
Liver Transpl; 7(11): S109-S118.
118. Gane E (2002).
Treatment of recurrent hepatitis C.
Liver Transpl; 8(10), Suppl. 1: S28-S37.
119. Gatti S, Arru M, Reggiani P, Rossi G, Tarantino A, Berardinelli L, Fassati LR (2002).
Combined liver and kidney transplantation: A single center experience.
Transplant Proc; 34: 3307-3310.

120. Geevarghese SK, Bradley AE, Wright JK, Chapman WC, Feurer I, Payne JL, Hunter EB, Prinson CW (1998).
Outcomes analysis in 100 liver transplant patients.
Am J Surg; 175: 348-353.
121. Ghaus N, Bohlega S, Rezeig M (2001).
Neurological complications in liver transplantation.
J Neurol; 248(12): 1042-1048.
122. Ghobrial RM (2002).
Retransplantation for recurrent hepatitis C.
Liver Transpl; 8(10), Suppl. 1: S38-S43.
123. Ginès P, Guevara M, Arroyo V, Rodés J (2003).
Hepatorenal syndrome.
Lancet; 362: 1819-1827.
124. Glanemann M, Settmacher U, Langrehr JM, Stange B, Haase R, Nuessler NC, Lopez-Hanninen E, Podrabsky P, Bechstein WO, Neuhaus P (2002).
Results of end-to-end cavocavostomy during adult liver transplantation.
World J Surg; 26(3): 342-347.
125. Goldstein G (1987).
Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.
Transplant Proc; 19 (Suppl): 1-6.
126. Gomez R, Hidalgo M, Marques E, Marin L, Loinaz C, Gonzalez I, Garcia I, Moreno E (2001).
Incidence and predisposing factors for incisional hernia in patients with liver transplantation.
Hernia; 5(4): 172-176.
127. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB (2001).
End-stage renal disease (ERSD) after orthotopic liver transplantation (OLT) using calcineurin-based immunotherapy.
Transplantation; 72(12): 1934-1939.
128. Gopal DV, Pfau PR, Lucey MR (2003).
Endoscopic management of biliary complications after orthotopic liver transplantation.
Curr Treat Gastroenterol; 6(6): 509-515.
129. Goresek MJ, Carey WD, Washington JA, Vogt DP, Broughan TA, Westveer MK (1993).
Selective bowel decontamination with quinolones and nystatin reduces gram-negative and fungal infections in orthotopic liver transplant recipients.
Cleve Clin J Med; 60: 139-144.
130. Goto T, Kino T, Hatanaka H, Nishiyama M, Okuhara M, Kohsaka M, Aoki H, Imanaka H (1987).
Discovery of FK506, a novel immunosuppressant isolated from *Streptomyces tsukubaensis*.
Transplant Proc; 19: 4-8.
131. Gregory CR, Huang X, Pratt RE, Dzau VJ, Shorthouse R, Billingham ME, Morris RE (1995).
Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement.
Transplantation; 59(5): 655-661.

132. Greif F, Bronsther OL, Van-Thiel DH, Casavilla A, Iwatsuki S, Tzakis A, Todo S, Fung JJ, Starzl TE (1994).
The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation.
Ann Surg; 219: 40-45.
133. Greig PD, Woolf GM, Sinclair SB, Abecassis M, Strasberg SM, Taylor BR, Blendis LM, Superina RA, Glynn MFX, Langer B, Levy GA (1993).
Treatment of primary liver graft nonfunction with prostaglandin E₁.
Transplantation; 48(3): 447-453.
134. Griffith BP, Shaw BW jr., Hardesty RL, Iwatsuki S, Bahnson HAT, Starzl TE (1985).
Veno-venous bypass without systemic anticoagulation for transplantation of the human liver.
Surg Gynecol Obstet; 160: 270-272.
135. Grzelak I, Zaleska M, Olszewski WL (1998).
Blood transfusions downregulate hematopoiesis and subsequently downregulate the immune response.
Transfusion; 38(11-12): 1104-1114.
136. Gubernatis G, Abendroth D, Haverich A, Bunzendahl H, Illner WD, Meyer HJ, Land W, Pichlmayr R (1988).
Technik der Multiorganentnahme.
Chirurg; 59: 461-468.
137. Guckelberger O, Bechstein WO, Neuhaus R, Luesebrink R, Lemmens HP, Kratschmer B, Jonas S, Neuhaus P (1997).
Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation.
Clin Transplant; 11(1):60-65.
138. Gütgemann A, Schriefers KH, Eßer G, Lie TS, Paquet KJ, Käufer C (1969).
Erfahrungsbericht über eine homologe Lebertransplantation.
Dtsch Med Wochenschr; 94: 1713-1717.
139. Guichelaar MMJ, Malinchoc M, Sibonga J, Clarke BL, Hay JE (2004).
Immunosuppressive and postoperative effects of orthotopic liver transplantation and bone metabolism.
Liver Transpl; 10: 638-647.
140. Gunsar F, Rolando N, Pastacaldi S, Patch D, Raimondo ML, Davidson B, Rolles K, Burroughs AK (2003).
Late hepatic artery thrombosis after orthotopic liver transplantation.
Liver Transpl; 9(6):605-611.
141. Haagsma EB, Hagens VE, Schaapveld M, van den Berg AP, de Vries EGE, Klompmaaker IJ, Slooff MJ, Jansen PL et al (2001).
Increased cancer risk after liver transplantation: a population-based study.
J Hepatol; 34(1): 84-91.
142. Hakala P, Hiippala S, Syrjälä, Randell T (1999).
Massive blood transfusion exceeding 50 units of plasma poor red cells or whole blood: the survival rate and the occurrence of leukopenia and acidosis.
Injury; 30: 619-622.
143. Hammer C (1995).
Immunreaktion und Immunsuppression bei Transplantationspatienten.
Intensiv; 3: 16-20.

144. Hay JE (2003).
Osteoporosis in liver diseases and after liver transplantation.
J Hepatol.; 38(6): 856-865. Review.
145. Hebert MF, Ascher NL, Lake JR, Emond J, Nikolai B, Linna TJ, Roberts JP (1999).
Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients.
Transplantation; 67(5): 707-712.
146. Heinemann A, Sterneck M, Kuhlencordt R, Rogiers X, Schulz KH, Queen B, Wischhusen F, Puschel K (1998).
Carbohydrate-deficient transferrin: diagnostic efficiency among patients with end-stage liver disease before and after liver transplantation.
Alcohol Clin Exp Res; 22(8): 1806-1812.
147. Hellgren A, Berglund B, Gunnarson U, Hansson K, Norberg U, Backmann L (1998).
Health-related quality of life after liver transplantation.
Liver Transplant Surg; 4: 215-221.
148. Henne-Bruns D (1994).
Organ donation.
In: Atlas of liver, pancreas, and kidney transplantation, Kremer B, Broelsch CE, Henne-Bruns D (Hrsg.); Thieme-Verlag: 1-35.
149. Herrero JI, Quiroga J, Sangro B, Giral M, Gomez-Manero N, Pardo F, Alvarez-Cienfuegos J, Prieto J (1999).
Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
Liver Transpl Surg; 5(5): 414-420.
150. Herrero JI, Lucena JF, Quiroga J, Sangro B, Pardo F, Rotellar F, Alvarez-Cienfuegos J, Prieto J (2003).
Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy.
Am J Transplant; 3(11): 1407-1412.
151. Hintze RE, Abou-Rebyeh H, Adler A, Veltzke W, Langrehr JM, Wiedenmann B, Neuhaus P (1999).
Endoscopic therapy of ischemia-type biliary lesions in patients following orthotopic liver transplantation.
Z Gastroenterol; 37(1): 13-20.
152. Hunt CM, Tart JS, Dowdy E, Bute BP, Williams DM, Clavien PA (1996).
Effect of orthotopic liver transplantation on employment and health status.
Liver Transpl Surg; 2(2): 148-153.
153. Hunt CM, Camargo CA Jr, Dornitz JA, Bute BP, Clavien PA (1998).
Effect of postoperative complications on health and employment after liver transplantation.
Clin Transpl; 12(2): 99-103
154. Jain A, Venkataramanan R, Fung JJ, Warty V, Fung J, Todo S, Starzl TE (1993).
FK506 and pregnancy in liver transplant patients under tacrolimus.
Transplantation; 56(6): 1588-1589.
155. Jain A, Venkataramanan R, Fung JJ, Gartner JC, Lever J, Balan V, Warty V, Starzl TE (1997).
Pregnancy after liver transplantation under tacrolimus.
Transplantation; 64(4): 559-565.

156. Jain A, Brody D, Hamad I, Rishi N, Kanal E, Fung J (2000).
Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus.
Transplantation; 69(1): 172-176.
157. Jain A, Reyes J, Marcos A, Mazariegos G, Eghtesad B, Fontes PA, Cacciarelli TV, Marsh JW, de Vera ME, Rafail A, Starzl T, Fung JJ (2003).
Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years.
Transplantation; 76(5): 827-832.
158. Janssen H, Lange R, Erhard J, Malago M, Eigler FW, Broelsch CE (2002).
Causative factors, surgical treatment and outcome of incisional hernia after liver transplantation.
Br J Surg; 89(9): 1049-1054.
159. Jauhar S, Talwalkar JA, Schneekloth T, Jowsey S, Wiesner RH, Menon KV (2004).
Analysis of risk factors that predict alcohol relapse following liver transplantation.
Liver Transpl; 10(3): 408-411.
160. Jenkinson C, Fitzpatrick R, Argyle M (1988).
The Nottingham Health Profile: an analysis of its sensitivity in differentiating illness groups.
Soc Sci Med; 27(12): 1411-1414.
161. Jenkinson C, Coulter A, Wright L (1993).
Short Form 36 (SF 36) health survey questionnaire: normative data for adults working age.
BMJ; 306:1437-1440.
162. Jeyarajah DR, McBride M, Klintmaln GB, Gonwa TA (1997).
Combined liver-kidney transplantation: what are the indications?
Transplantation; 64(8): 1091-1096.
163. Jeyarajah DR, Gonwa TA, McBride M, Testa G, Abbasoglu O, Husberg BS, Levy MF, Goldstein RM, Klintmalm GB (1997).
Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant.
Transplantation; 64(12): 1760-1765.
164. John PR, Thuluvath PJ (2002).
Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus.
Liver Transpl; 8(8): 708-713.
165. Johnston TD, Gates R, Reddy KS, Nickl J, Ranjan D (2000).
Nonoperative management of bile leaks following liver transplantation.
Clin Transplant; 14: 365-369.
166. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J (2002).
Cardiovascular morbidity and mortality after orthotopic liver transplantation.
Transplantation; 73(6): 901-906.
167. Jonas S, Rayes N, Neumann U, Neuhaus R, Bechstein WO, Guckelberger O, Tullius SG, Serke S, Neuhaus P (1997).
De novo malignancies after liver transplantation using tacrolimus-based or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody.
Cancer; 80(6): 1141-1150.

168. Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, Settmacher U, Neuhaus P (2001).
Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis.
Hepatology; 33: 1080-1086.
169. Kahan BD (1989).
Cyclosporin.
New Engl J Med; 321: 1725-1738.
170. Kainz A, Harabacz I, Cowlrick IS, Gadgil S, Hagiwara D (2000).
Analysis of 100 pregnancy outcomes in women treated systemically with tacrolimus.
Transpl Int; 13 (Suppl): S299-300.
171. Kalayoglu M, Sollinger WH, Stratta RJ, D'Allessandro AM, Hoffman RM, Pirsch JD, Belzer FO (1988).
Extended preservation of the liver for clinical transplantation.
Lancet; 1: 617-619.
172. Karam VH, Gasquet I, Delvart V, Hiesse C, Dorent R, Danet C, Samuel D, Charpentier B, Gandjbakhch I, Bismuth H, Castaing D (2003).
Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation.
Transplantation; 76(12): 1699-1704.
173. Karatzas T, Lykaki-Karatzas E, Webb M, Nery J, Tsaroucha A, Demirbas A, Khan F, Ciancio G, Montalvo B, Reddy R, Schiff E, Miller J, Tzakis AG (1997).
Vascular complications, treatment, and outcome following orthotopic liver transplantation.
Transplant Proc; 29(7): 2853-2855.
174. Keeffe BG, Valentine H, Keeffe EB (2001).
Detection and treatment of coronary artery disease in liver transplant candidates.
Liver Transpl; 7(9): 755-761.
175. Kelly PA, Gruber SA, Behbod F, Kahan BD (1997).
Sirolimus, a new potent immunosuppressive agent.
Pharmacotherapy; 17: 1148-1156.
176. Khalili M, Watson Lim J, Bass N, Ascher NL, Roberts JP, Terrault NA (2004).
New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection.
Liver Transpl; 10(3): 349-355.
177. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, Goto T, Okuhara M, Kohsaka M, Aoki H (1987).
FK506, a novel immunosuppressant isolated from *Streptomyces tsukubaensis*.
II. Immunosuppressive effect of FK506 in vitro.
J Antibiot Tokyo; 40: 1256-1265.
178. Knaus WA, Draper EA, Wagner DP, Zimmermann JE (1985).
APACHE II: A severity of disease classification system.
Crit Care Med; 13: 818-829.
179. Knaus WA, Wagner DP, Draper EA (1991).
The APACHE III prognostic system: Risk prediction of hospital mortality for critically ill hospitalized adults.
Chest; 100: 1619-1636.

180. Königsrainer A, Steurer W, Margreiter R (1999).
Multiple abdominal organ procurement for multiple recipient.
Current Opinion of Organ Transplantation; 4: 135-138.
181. Kovarik J, Breidenbach T, Gerbeau C, Korn A, Schmidt AG, Nashan B (1998).
Disposition and immunodynamicity of basiliximab in liver allograft recipients.
Clin Pharmacol Ther; 64: 66-72.
182. Kramer L, Horl WH (2002).
Hepatorenal syndrome.
Semin Nephrol; 22(4): 290-301.
183. Krawczyk M, Nyckowski P, Zieniewicz K, Pawlak J, Michalowicz B, Malkowski P,
Paluszkiewicz R, Paczek L, Wroblewski T, Pacho R, Grzelak I, Gackowski W (2000).
Biliary complications following liver transplantation.
Transplant Proc; 32(6): 1429-1431.
184. Kremer B (1994).
Standard techniques in orthotopic liver transplantation.
In: Atlas of liver, pancreas, and kidney transplantation, Kremer B, Broelsch, Henne-Bruns D
(eds.) Thieme-Verlag: 36-53.
185. Lang H, Kamler M, Herold U, Malago M, Jakob H, Broelsch CE (2002).
Die Spenderorganentnahme.
Chirurg; 73:517-537.
186. Langnas AN, Marujo W, Stratta RJ, Wood RP, Shaw BW Jr (1991).
Vascular complications after orthotopic liver transplantation.
Am J Surg; 161(1):76-83.
187. Lavezzo B, Rizetto M (1999).
Treatment of recurrent hepatitis C after liver transplantation.
J Hepatol; 31(Suppl 1): 222-226.
188. Lebeau G, Yanaga K, Marsh JW, Tzakis AG, Makowka L, Gordon RD, Todo S, Stieber AC,
Iwatsuki S, Starzl TE (1990).
Analysis of surgical complications after 397 hepatic transplantations.
Surg Gynecol Obstet; 170(4): 317-322.
189. Leelaudomlapi S, Bramhall SR, Gunson BK, Candinas D, Buckels JA, McMaster P, Mirza DF,
Mayer AD (2003).
Hepatic-artery aneurysm in adult liver transplantation.
Transpl Int; 16(4): 257-261.
190. Lerut J, Gordon RD, Iwatsuki S, Esquivel CO, Todo S, Tsakis A, Starzl TE (1987).
Biliary tract complications in human orthotopic liver transplantation.
Transplantation; 43(1): 47-51.
191. Lerut JP, Mazza D, van Leeuw V, Laterre PF, Donataggio M, de Ville de Goyet J, Van Beers B,
Bourlier P, Goffette P, Puttemans T, Otte JB (1997).
Adult liver transplantation and abnormalities of splanchnic veins: experience in 53 patients.
Transpl Int; 10(2): 125-132.
192. Lerut J (1998).
Portal vein thrombosis and liver transplantation.
Transpl Int; 11(1): 70.

193. LeTreat YP, Delpero JR, Dousset B, Cherqui D, Segol P, Manton G, Hannoun L, Benhamou G, Launois B, Boillot O, Domergue J, Bismuth H (1997).
Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report.
Ann Surg; 225(4): 355-364. Review.
194. Levy MF, Jennings L, Abouljoud MS, Mulligan DC, Goldstein RM, Husberg BS, Gonwa TA, Klintmalm GB (1995)
Quality of life improvements at one, two, and five years after liver transplantation.
Transplantation; 59(4): 515-518.
195. Levy GA (2001).
Long-term immunosuppression and drug interactions.
Liver Transpl; 11 (Suppl 1): S53-S59.
196. Littlefield C, Abbey S, Fiducia D, Cardella C, Greig P, Levy G, Maurer J, Winton T (1996).
Quality of life following transplantation of the heart, liver and lungs.
Gen Hosp Psychiatry; 18 (Suppl): 36-47.
197. Llovet JM, Burroughs A, Bruix J (2003).
Hepatocellular Karzinoma.
Lancet; 362: 1907-1917.
198. Lloyd DM, Broelsch CE (1994).
Transplantation of liver segments.
In: *Atlas of liver, pancreas, and kidney transplantation*, Kremer B, Broelsch CE, Henne-Bruns D (eds.). Thieme-Verlag: 54-94.
199. Loinaz C, Clemares E, Marqués E, Paseiro G, Gómez R, González-Pinto I, Jiménez C, Garcia I, Moreno E (1999).
Labor status of 137 patients with liver transplantation.
Transplant Proc; 31: 2470-2471.
200. Lok ASF (2002).
Treatment of recurrent hepatitis B infection in liver transplant recipients.
Liver Transpl; 8(10), Suppl 1: S67-S73.
201. Losada I, Cuervas-Mons V, Millan I, Damaso D (2002).
Early infection in liver transplant recipients: incidence, severity, risk factors and antibiotic sensitivity of bacterial isolates.
Enferm Infecc Microbiol Clin; 20(9): 422-430.
202. Lynn M, Abreo K, Zibari G, McDonald J (2001).
End-stage renal disease in liver transplants.
Clin Transplant; 15 (Suppl 6): 66-69.
203. Madariaga J, Tzakis A, Zajko AB, Tzoracoleftherakis E, Tepetes K, Gordon R, Todo S, Starzl TE (1992).
Hepatic artery pseudoaneurysm ligation after orthotopic liver transplantation--a report of 7 cases.
Transplantation; 54(5): 824-828.
204. Maggi U, Rossi G, Colledan M, Fassati LR, Ferla F, Gridelli B, Reggiani P, Lomonte A (1991).
Major surgical complications after 73 consecutive liver transplantations.
Ann Chir; 45(6): 476-679.

205. Maheshwari A, Mishra R, Thuluvath PJ (2004).
Post-liver transplant anemia: etiology and management.
Liver Transpl; 10(2): 165-173.
206. Majno PE, Adam R, Bismuth H, Castaing D, Ariche A, Krissat J, Perrin H, Azoulay D(1997).
Influence of preoperative transarterial lipiodol chemoembolization on resection and
transplantation for hepatocellular Karzinoma in patients with cirrhosis.
Ann Surg; 226(6): 688-701.
207. Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman
ZD, Koury K, Ling M, Albrecht JK (2001).
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b for initial treatment of
chronic hepatitis C: a randomized trial.
Lancet; 358: 958-965.
208. Manns MP, Neuhaus P, Atkinson GF, Griffin KE, Barnass S, Vollmar J, Yeang Y, Young CL
(2001).
Famciclovir treatment of hepatitis B infection following liver transplantation: a long-term,
multi-center study.
Transpl Infect Dis; 3(1): 16-23.
209. Margarit C, Hidalgo E, Lázaro JL, Murio E, Charco R, Balsells J (1998).
Biliary complications secondary to late hepatic artery thrombosis in adult liver transplant
recipient.
Transpl Int; 11 (Suppl 1): S251-254.
210. Margreiter R (1999).
Organentnahme – Logistisches und technisches Know-how.
Viszeralchirurgie; 34: 285-290.
211. Margreiter R, Königsrainer A, Spechtenhauser B, Ladurner R, Pomarolli A, Hörmann Ch,
Steurer W, Graziadei I, Vogel W (2002).
Our experience with combined liver-kidney transplantation: an update.
Transplant Proc; 34: 2491-2492.
212. Maring JK, Klompaker IJ, Zwaveling JH, Kranenburg K, Ten Vergert EM, Slooff MJ (1997).
Poor initial graft function after orthotopic liver transplantation: can it be predicted and does it
affect outcome? An analysis of 125 adult primary transplantations.
Clin Transplant; 11: 373-379.
213. Maring JK, Zwaveling JH, Klompaker IJ, van der Meer J, Slooff MJ (2002).
Selective bowel decontamination in elective liver transplantation: no improvement in
endotoxaemia, initial graft function and post-operative morbidity.
Transpl Int; 15: 329-334.
214. Markmann JF, Markowitz JS, Yersiz H, Morrissey M, Farmer DG, Goss J, Ghobrial R,
McDiarmid SV, Striebling Martin p, Goldstein LI, Seu P, Shakleton C, Bussutil RW (1997).
Long-term survival after retransplantation of the liver.
Ann Surg; 226: 408-418.
215. Mazzaferro V, Regalia E, Doci R, Andreole S, Pulvirenti A, Bozzetti F, Montalto F (1996).
Liver transplantation for the treatment of small hepatocellular Karzinomas in patients with
cirrhosis.
N Engl J Med; 334: 693-699.

216. McDiarmid SV, Klintmalm GB, Busuttill RG (1993).
FK506 conversion for intractable rejection of liver allograft.
Transpl Int; 6: 305-312.
217. McDiarmid SV (1996).
Mycophenolate mofetil in liver transplantation.
Clin Transplant; 10: 140-145.
218. McDiarmid SV (1999).
Mycophenolate Mofetil as induction therapy after liver transplantation.
Liver Transpl Surg; 5(4 Suppl 1): S85-89.
219. McLaughlin K, Wajstaub S, Marotta P, Adams P, Grant DR, Wall WJ, Jevnikar AM, Rizkalla KS (2000).
Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C.
Liver Transpl; 6(5): 570-574.
220. McMaster P, Herbertson B, Cusick C, Calne RY, Williams R (1978).
Biliary sludging following liver transplantation in man.
Transplantation; 25(2): 56-62.
221. Mehta CR, Patel NR (1998).
Exact inference for categorical data.
In: Armitage P, Colton T (eds.): *Encyclopedia of Biostatistics*. New York, Wiley & Sons.
222. Menghini G (1953).
One-second needle biopsy of the liver.
Gastroenterology; 35:190-199.
223. Meyer CG, Penn I, James L (2000).
Liver transplantation for cholangioKarzinoma: results in 207 patients.
Transplantation; 69(8): 1633-1637.
224. Mihatsch MJ, Kyo M, Morozumi K, Yamaguchi Y, Nickleit V, Ryffel B (1998).
The side-effects of cyclosporine-A and tacrolimus.
Clin Nephrol; 49: 356-363.
225. Mita MM, Mita A, Rowinsky EK (2003).
The Molecular Target of Rapamycin (mTOR) as a Therapeutic Target Against Cancer.
Cancer Biol Ther; 2(4 Suppl 1): S169-177.
226. Molmenti EP, Klintmalm GB (2002).
Liver transplantation in association with hepatocellular Karzinoma: an update of the International Tumor Registry.
Liver Transpl; 8: 736-748.
227. Moore KA, Jones RM, Angus P, Hardy K, Burrows G (1992).
Psychosocial adjustments to illness: quality of life following liver transplantation.
Transplant Proc; 24(5): 2257-2258.
228. Moreno A, Meneu JC, Moreno E, Garcia I, Loinaz C, Jimenez C, Gomez R, Abradelo M (2003).
Results in split-liver transplantation.
Transplant Proc; 35(5): 1810-1811.
229. Moreno JM, Rubio E, Gomez A, Lopez-Monclus J, Herreros A, Revilla J, Navarrete E, Sanchez Turion V, Jimenez M, Cuervas-Mons V (2003).

- Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation.
Transplant Proc; 35(5): 1874-1876.
230. Moreno-Gonzalez E, Meneu-Diaz JC, Garcia G, Jimenez Romero C, Loinaz Seguro C et al (2003).
Simultaneous liver-kidney transplant for combined renal and hepatic end-stage disease.
Transplant Proc; 35: 1863-1865.
231. Morris RE, Hoyt EG, Murphy MP, Eugui EM, Allison AC (1990).
Mycophenolic acid morphelinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis.
Transplant Proc; 22(4): 1659-1562.
232. Moser MAJ, Wall WJ (2001).
Management of biliary problems after liver transplantation.
Liver Transpl; 7(11), Suppl 1: S46-S52.
233. Muller V, Lehner M, Klein P, Hohenberger W, Ott R.(2003).
Incisional hernia repair after orthotopic liver transplantation: a technique employing an inlay/onlay polypropylene mesh.
Langenbecks Arch Surg; 388(3): 167-173.
234. Munoz SJ (1996).
Long-term management of the liver transplant recipient.
Med Clin North Am; 80(5): 1103-1120.
235. Munoz SJ, Rothstein KD, Reich D, Manzarbeitia C (2000).
Long-term care of the liver transplant recipient.
Clin Liver Dis; 4(3): 691-710.
236. Muralidharan V, Imber C, Leelaudomlipi S, Gunson BK, Buckels JAC, Mirza DF, Mayer AD, Bramhall SR (2004).
Arterial conduits for hepatic artery revascularisation in adult liver transplantation.
Transpl Int; 17: 163-168.
237. Nagy S, Bush MC, Berkowitz R, Fishbein TM, Gomez-Lobo V (2003).
Pregnancy outcome in liver transplant recipient.
Obstet Gynecol; 102(1): 121-128.
238. Navasa M, Bustamante J, Marroni C, Gonzalez E, Andreu H, Esmatjes E, Garcia-Valdecasas JC, Grande L, Cirera I, Rimola A, Rodes J (1996).
Diabetes mellitus after liver transplantation: prevalence and predictive factors.
J Hepatol; 25(1): 64-71.
239. Neal DAJ, Gimson AES, Gibbs P, Alexander GJM (2001).
Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and body weight.
Liver Transpl; 7(6): 533-539.
240. Neal DAJ, Brown MJ, Wilkinson IB, Byrne CD, Alexander GJM (2004).
Is there disparity between risk and incidence of cardiovascular disease after liver transplant?
Transplantation; 77(1): 93-99.
241. Neau-Cransac M, Morel D, Bernard PH, Merville P, Revel P, Potaux L, Saric J (2002).
Renal failure after liver transplantation: outcome after calcineurin inhibitor withdrawal.
Clin Transplant; 16: 368-373.

242. Nemecek P, Ondrasek J, Studenik P, Hokl J, Cerny J (2001).
Biliary complications in liver transplantation.
Ann Transplant; 6(2): 24-28.
243. Neuberger J (1999).
Incidence, timing, and risk factors for acute and chronic rejection. Review.
Liver Transpl Surg; 5(4): S30-S36.
244. Neuberger J, Schulz KH, Day C, Fleig W, Berlakovich GA, Berenguer M, Pageaux GP, Lucey M, Horsmans Y, Burroughs A, Hockerstedt K (2002).
Transplantation for alcoholic liver disease.
J Hepatol; 36: 130-137.
245. Neuhaus P, Neuhaus R, Pichlmayr R, Vonnahme F (1982).
An alternative technique of biliary reconstruction after liver transplantation.
Res Exp Med Berl; 180: 239-245.
246. Neuhaus P, Steffen R, Blumhardt G, Bechstein WO, Lemmens HP, Keck H, Rossaint R, Slama (1991).
Verbesserte Überlebenschancen nach Lebertransplantation durch Verminderung postoperativer Komplikationen.
Z Gastroenterol; 29: 169-172.
247. Neuhaus P, Blumhardt G, Bechstein WO, Steffen R, Platz K-P, Keck H (1994).
Technique and results of biliary reconstruction using side-to-side choledochocholedochostomy in 300 orthotopic liver transplants.
Ann Surg; 219: 426-434.
248. Neuhaus P, Blumhardt G, Bechstein WO, Platz K-P, Jonas S, Mueller AR, Langrehr JM, Lohmann R, Schattenfroh N, Knoop M, Keck H, Lemmens P, Raakow R, Lüsebrink R, Slama KJ, Lobeck H, Hopf U (1995).
Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience.
Transplantation; 59(1): 31-40.
249. Neuhaus P, Langrehr JM, Williams R, Calne RY, Pichlmayr R, McMaster P (1997).
Tacrolimus-based immunosuppression after liver transplantation: a randomized study comparing dual versus triple low-dose oral regimen.
Transpl Int; 10: 253-261.
250. Neuhaus R, Kubo A, Lohmann R, Rayes N, Hierholzer J, Neuhaus P (1999).
Calcitriol in prevention and therapy of osteoporosis after liver transplantation.
Transplant Proc; 31(1-2): 472-473.
251. Neuhaus P, Jonas S, Bechstein WO, Wex C, Kling N, Settmacher U, Al-Abadi H (1999).
Liver transplantation for hepatocellular carcinoma.
Transplant Proc; 31(1-2): 469-471.
252. Neuhaus P, Klupp J, Langrehr JM (2001).
mTOR inhibitors: an overview. Review.
Liver Transpl; 7(6): 473-484.
253. Neumann UP, Kaisers U, Langrehr JM, Glanemann M, Müller AR, Lang M, Jorres A, Settmacher U, Bechstein WO, Neuhaus P (2000).
Administration of prostacyclin after liver transplantation: a placebo controlled randomized trial.
Clin Transplant; 14(1): 70-74.

254. Nicholas JJ, Oleske D, Robinson LR, Switala JA, Tarter R (1994).
The quality of life after orthotopic liver transplantation: an analysis of 166 cases.
Arch Phys Med Rehabil; 75(8): 431-435.
255. Nüssler NC, Settmacher U, Haase R, Stange B, Heise M, Neuhaus P (2003).
Diagnosis and treatment of arterial steal syndromes in liver transplant recipients.
Liver Transpl; 9(6): 596-602.
256. Padovan CS, Sostak P, Straube A (2000).
Neurological complications after organ transplantation.
Nervenarzt; 71(4): 249-258. Review.
257. Pageaux GP, Michel J, Coste V, Perney P, Possoz P, Perrigault PF, Navarro F, Fabre JM, Domergue J, Blanc P, Larrey D (1999).
Alcoholic cirrhosis is a good indication for liver transplantation, even for cases of recidivism.
Gut; 45(3): 421-426.
258. Pageaux GP, Bismuth M, Perney P, Costes V, Jaber S, Possoz P, Fabre JM, Navarro F, Blanc P, Domergue J, Eledjam JJ, Larrey D (2003).
Alcoholic relapse after liver transplantation for alcoholic liver disease: does it matter?
J Hepatol; 38(5): 629-634.
259. Paramesh AS, Roayaie S, Doan Y, Schwartz ME, Emre S, Fishbein T, Florman S, Gondolesi GE, Krieger N, Ames S, Bromberg JS, Akalin E. (2004).
Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease.
Clin Transplant; 18(1): 94-99.
260. Park KM, Hay JE, Lee SG (1996).
Bone loss after orthotopic liver transplantation: FK versus Cyclosporine.
Transplant Proc; 28: 1738-1740.
261. Parolin MB, Coelho JC, Costa PB, Pimentel SK, dos Santos-Neto LE, Vayego SA (2001).
Return to work of adults after liver transplantation.
Arq Gastroenterol; 38(3): 172-175.
262. Pascher A, Jonas S, Neuhaus P (2003).
Intrahepatic cholangioKarzinoma: indication for transplantation.
J Hepatobiliary Pancreat Surg; 10(4):282-287.
263. Pascher A (2003).
Xenotransplantation der Leber.
In: *Aktuelle Aspekte der Lebertransplantation*. P Neuhaus und R Pfitzmann (Hrsg.), UNI-MED Verlag, Bremen, 2003: 68-70.
264. Patel R, Paya CV (1997).
Infections in solid organ-transplant recipients.
Clin Microbiol Rev; 10: 86-124.
265. Paul A (1994).
Outcome nach konservativer und chirurgischer Therapie des akuten und chronischen Leberversagens.
Habilitationsschrift der Universität Köln, 1994.
266. Pawarode A, Fine DM, Thuluvath PJ (2003).
Independent risk factors and natural history of renal dysfunction in liver transplant recipients.
Liver Transplant; 9(7); 741-747.

267. Paya CV (2001).
Prevention of fungal and hepatitis virus infections in liver transplantation.
Clin Infect Dis; 33: S47-S52.
268. Paya CV (2002).
Prevention of fungal infection in transplantation.
Transpl Infect Dis; 4, Suppl 3: 46-51.
269. Penn I (1988).
Secondary neoplasm as a consequence of transplantation and cancer therapy.
Cancer Detect Prev; 12(1-6): 39-57.
270. Penn I (1991).
The changing pattern of posttransplant malignancies.
Transplant Proc; 23(1): 1101-1103.
271. Penn I (1996).
Posttransplantation de novo tumors in liver allograft recipients.
Liver Transpl Surg; 2: 52-59.
272. Penn I (1998).
Primary malignancies of the hepato-biliary-pancreatic system in organ allograft recipients.
J Hepatobiliary Pancreat Surg; 5(2): 157-164.
273. Perillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, Martin P, Dienstag J, Adams P, Dickson R, Anschuetz G, Bell S, Condreay L, Brown N; Lamivudine North American Transplant Group (2001).
The Lamivudine North American Transplant Group. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.
Hepatology; 33: 424-432.
274. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P, Murray A (2000).
Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.
Hepatology; 32(1): 129-134.
275. Pfitzmann R, Klupp J, Langrehr JM, R Neuhaus, Settmacher U, Steinmüller T, Neuhaus P (2003).
Mycophenolate Mofetil for immunosuppression after liver transplantation.
Transplantation; 76(1): 130-136.
276. Pinna AD, Smith CV, Furukawa H, Starzl TE, Fung JJ (1996).
Urgent revascularization of liver allografts after early hepatic artery thrombosis.
Transplantation; 62: 1584-1587.
277. Platz KP, Solliger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC (1991).
RS-61443 – a new potent immunosuppressive agent.
Transplantation; 51(1): 27-31.
278. Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P (1994).
Nephrotoxicity following orthotopic liver transplantation: a comparison between cyclosporine and FK506.
Transplantation; 58(2): 170-178.
279. Platz KP, Tullius SG, Müller AR, Schumacher G, Nüssler N, Neuhaus R, Bechstein WO, Lobeck H, Neuhaus P (1996).

- Incidence and outcome of chronic rejection in CyA- and FK506-treated patients.
Transplant Proc; 28: 3183-3184.
280. Platz KP, Mueller AR, Zytowski M, Lemmens P, Lobeck H, Neuhaus P (1996).
 Management of acute steroid-resistant rejection after liver transplantation.
World J Surg; 20: 1052-1059.
281. Platz KP, Mueller AR, Neuhaus R, Keck HH, Lobeck H, Neuhaus P (1997).
 FK 506 and Mycophenolat Mofetil rescue for acute steroid-resistant and chronic rejection after
 liver transplantation.
Transplant Proc; 29(7): 2872-2874.
282. Platz KP, Mueller AR, Neuhaus P (1997).
 Indications for mycophenolate mofetil therapy after liver transplantation.
Transplant Proc; 29(7): 2880-2881.
283. Platz KP, Mueller AR, Willimski C, Mansoorian B, Berg T, Neuhaus R, Hopf U, Radke C,
 Neuhaus P (1998).
 Indication for mycophenolate mofetil therapy in hepatitis C patients undergoing liver
 transplantation.
Transplant Proc; 30(5): 2232-2233.
284. Platz KP, Mueller AR, Spree E, Schumacher G, Nussler NC, Rayes N, Glanemann M,
 Bechstein WO, Neuhaus P (2000).
 Liver transplantation for alcoholic cirrhosis.
Transpl Int; 13, Suppl 1: 127-130.
285. Plotkin JS, Scott VL, Pinna A, Dobsch BP, de Wolf AM, Kang Y (1996).
 Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver
 transplantation.
Liver Transpl Surg; 2(6): 426-430.
286. Pokorny H, Gruenberger T, Soliman T, Rockenschaub S, Längle F, Steininger R (2000).
 Organ survival after primary dysfunction of liver grafts in clinical orthotopic liver
 transplantation.
Transpl Int; 13 (Suppl 1): S154-S157.
287. Porte RJ, Ploeg RJ, Hansen B, van Bockel JH, Thorogood J, Persijn GG, Hermans J, Terpstra
 OT (1998).
 Long-term graft survival after liver transplantation in the UW era: late effects of cold ischemia
 and primary dysfunction. European Multicentre Study Group.
Transpl Int; 11, Suppl 1: S164-S167.
288. Postma R, Haagsma EB, Peeters PMJG, van den Berg AP, Slooff MJH (2004).
 Replantation of the liver in adults: outcome and predictive factors of survival.
Transplant Int; 17: 234-240.
289. Preeti RJ, Thuluvath PJ (2002).
 Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with
 those without diabetes mellitus.
Liver Transpl; 8(8): 708-713.
290. Price CE, Lowe D, Cohen AT, Reid FD, Forbes GM, McEwen J, Williams R (1995).
 Prospective study of the quality of life in patients assessed for liver transplantation: outcome in
 transplanted and not transplanted groups.
J R Soc Med; 88(3):130-135.

291. Pruhti J, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR, Sieinbrecher UP, Fong TL (2001).
Analysis of causes of death in liver transplant recipients who survived more than 3 years.
Liver Transplant; 7 (9): 811-815.
292. Raakow R, Steffen R, Bechstein WO, Blumhardt G, Neuhaus P (1990).
Selective bowel decontamination effectively prevents gram-negative bacterial infections after liver transplantation.
Transplant Proc; 22: 1556-1557.
293. Raisanen-Sokolowski A, Vuoristo P, Myllarniemi M, Yilmaz S, Kallio E, Hayry P (1995).
Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts.
Transpl Immunol; 3(4): 342-351.
294. Raisanen-Sokolowski A, Myllarniemi M, Hayry P, Yilmaz S, Kallio E, Hayry P (1994).
Effect of mycophenolate mofetil on allograft arteriosclerosis (chronic rejection).
Transplant Proc; 26(3): 3225.
295. Raisanen-Sokolowski A, Aho P, Myllarniemi M, Kallio E, Hayry P (1995).
Inhibition of early chronic rejection in rat aortic allografts by mycophenolate mofetil (RS61443).
Transplant Proc; 27(1): 435.
296. Ramsey PS, Hay JE, Ramin KD (1998).
Successful pregnancy following orthotopic liver transplantation for idiopathic Budd-Chiari syndrome.
J Matern Fetal Med; 7(5): 235-237.
297. Randoux O, Gambiez L, Navarro F, Declerck N, Labalette M, Dessaint JP, Pruvot FR (1995).
Post-liver transplantation thrombocytopenia: a persistent immunologic sequestration ?
Transplant Proc; 27(2): 1710-1711.
298. Rayes N, Seehofer D, Hansen S, Boucsein K, Muller AR, Serke S, Bengmark S, Neuhaus P (2002).
Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients.
Transplantation; 74(1): 123-127.
299. Reich D, Rothstein K, Manzarbeitia C, Munoz SJ (1998).
Common medical diseases after liver transplantation.
Semin Gastrointest Dis; 9(3): 110-125.
300. Renz JF, Yersiz H, Reichert PR, Hisatake GM, Farmer DG, Emond JC, Busuttil RW (2003).
Split-liver transplantation: a review.
Am J Transplant.; 3(11): 1323-35.
301. Reuben A (2001).
Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity.
Liver Transpl; 7(11), Suppl 1: S13-S21.
302. Riely CA (2001).
Contraception and pregnancy after liver transplantation.
Liver Transpl; 7 (Suppl 11): S74-76.

303. Riether AM, Smith SL, Lewison BJ, Cotsonis GA, Epstein CM (1992).
Quality of life changes and psychiatric and neurocognitive outcome after heart and liver transplantation.
Transplantation; 54(3): 444-450.
304. Rossaint R, Slama K, Jäger M, Konrad M, Pappert D, Bechstein WO, Blumhardt G, Neuhaus P, Falke KJ (1990).
Fluid restriction and early extubation for successful liver transplantation.
Transplant Proc; 22: 1533-1534.
305. Roumilhac D, Poyet G, Sergent G, Declerck N, Karoui M, Mathurin P, Ernst O, Paris JC, Gambiez L, Pruvot FR (2003).
Long-term results of percutaneous management for anastomotic biliary stricture after orthotopic liver transplantation.
Liver Transplant; 9(4): 394-400.
306. Saab S, Wang V, Ibrahim AB, Durazo F, Han S, Farmer DG, Yersiz H, Morrissey M, Goldstein LI, Ghobrial RM, Busuttill RW (2003).
MELD score predicts 1-year patient survival post-orthotopic liver transplantation.
Liver Transpl ; 9(5): 473-476.
307. Saigal S, Norris S, Muisan P, Rela M, Heaton N, O'Grady J (2002).
Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients under going liver transplantation.
Liver Transpl; 8(5): 482-487.
308. Samuel D, Féray C (1999).
Recurrence of hepatitis C virus infection after liver transplantation.
J Hepatol; 31(Suppl. 1): 217-221.
309. Samuel D (2002).
I favor therapy of hepatitis c virus recurrence after transplantation.
Liver Transpl; 8(10): S55-S58.
310. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, Cohard M, Reynes M, Chevallier M, Ducerf C, Baulieux J, Geffner M, Albrecht JK, Bismuth H, Trepo C (2003).
Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
Gastroenterology; 124: 642-650.
311. Sanchez EQ, Marubashi S, Jung G, Levy MF, Goldstein RM, Molmenti EP, Fasola CG, Gonwa TA, Jennings LW, Brooks BC, Klintmalm GB (2002).
De novo tumors after liver transplantation: A single-institution experience.
Liver Transpl; 8(3): 285-291.
312. Sanchez-Bueno F, Robles R, Ramirez P, Acosta F, Rodriguez JM, Lujan J, Pons JA, Aguilar J, Parrilla P (1994).
Hepatic artery complications after liver transplantation.
Clin Transplant; 8: 399-404.
313. Sarasin F, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A (2001).
Living donor liver transplantation for early hepatocellular Karzinoma: a life-expectancy and cost-effectiveness perspective.
Hepatology; 33: 1073-1079.

314. Salter JW, Kriegelstein CF, Issekutz AC, Granger DN (2001). Platelets modulate ischemia/reperfusion-induced leukocyte recruitment in the mesenteric circulation. *Am J Physiol Gastrointest Liver Physiol*; 281(6): 1432-1439.
315. Schemper M, Smith T (1996). A note on quantifying follow-up in studies of failure time. *Controlled Clinical Trials*; 17: 343-346.
316. Schiano TD, Kim-Schluger L, Gondolesi G, Miller CM (2001). Adult living donor liver transplantation: the hepatologist's perspective. *Hepatology*; 33: 3-9.
317. Schlitt HJ, Barkmann A, Böker KHW, Schmidt HH, Emmanouilidis N, Rosenau J, Bahr MJ, Tusch G, Manns MP, Nashan B, Klempnauer J (2001). Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. *Lancet*; 357: 587-591.
318. Seehofer D, Rayes N, Steinmuller T, Muller AR, Settmacher U, Neuhaus R, Radke C, Berg T, Hopf U, Neuhaus P (2001). Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation. *Liver Transpl*; 7(11): 976-982.
319. Seehofer D, Rayes N, Naumann U, Neuhaus R, Muller AR, Tullius SG, Berg T, Steinmuller T, Bechstein WO, Neuhaus P (2001). Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. *Transplantation*; 72(8): 1381-1385.
320. Sehgal SN, Molnar-Kimber K, Ocain T, Weichman BM (1995). Rapamycin: a novel immunosuppressive macrolide. *Med Res Rev*; 14: 1-22.
321. Sehgal SN (1995). Rapamune (Sirolimus, Rapamycin): An overview and mechanism of action. *Ther Drug Monit*; 17: 660-665.
322. Sehgal SN (1998). Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. *Clin Biochem*; 31(5): 335-340.
323. Settmacher U, Nussler NC, Glanemann M, Haase R, Heise M, Bechstein WO, Neuhaus P (2000). Venous complications after orthotopic liver transplantation. *Clin Transplant*; 14(3): 235-241.
324. Settmacher U, Stange B, Haase R, Heise M, Steinmuller T, Bechstein WO, Neuhaus P (2001). Arterial complications after liver transplantation. *Transpl Int*; 13(5): 372-378.
325. Settmacher U, Neuhaus P (2003). Innovation in der Leberchirurgie durch die Transplantation mit Lebendspende. *Chirurg*; 74: 536-546.

326. Settmacher U, Steinmüller T, Luck W, Eisele R, Theruvath T, Heise M, Neuhaus P (2003). Complex vascular reconstruction in living donor liver transplantation. *Transplant Int*; 16: 742–747.
327. Shaw BW, Martin DJ, Marquez JM, Kang YG, Bugbee AC, Iwatsuki S, Griffith BP, Hardesty RL, Bahnson HAT, Starzl TE (1984). Venous bypass in clinical liver transplantation. *Ann Surg*; 200: 524-534.
328. Sheiner PA, Magliocca JF, Bodian CA, Kim-Schluger L, Altaca G, Guarrera JV, Emre S, Fishbein TM, Guy SR, Schwartz ME, Miller CM (2000). Long-term medical complications in patients surviving = or >5 years after liver transplant. *Transplantation*; 69(5): 781-789.
329. Sherman S, Shaked A, Cryer HM, Goldstein LI, Busuttil RW (1993). Endoscopic management of biliary fistulas complicating liver transplantation and other hepatobiliary operations. *Ann Surg*; 218: 167-175.
330. Shiffman ML, Vargas HE, Everson GT (2003). Controversies in the management of hepatitis C virus infection after liver transplantation. *Liver Transplant*; 9(11): 1129-1144.
331. Smith DM, Agura E, Netto G, Collins R, Levy M, Goldstein R, Christensen L, Baker J, Altrabulsi B, Osowski L, McCormack J, Fichtel L, Dawson DB, Domiati-Saad R, Stone M, Klintmalm G (2003). Liver transplant-associated graft-versus-host disease. *Transplantation*; 75(1): 118-126.
332. Sobhonslidsuk A, Reddy KR (2002). Portal vein thrombosis: a concise review. *Am J Gastroenterol*; 97(3): 535-541.
333. Soliman T, Bodingbauer M, Langer F, Berlakovich GA, Wamser P, Rockenschaub S, Muehlbacher F, Steininger R (2003). The role of complex hepatic artery reconstruction in orthotopic liver transplantation. *Liver Transpl*; 9(9): 970-975.
334. Sollinger HW, Belzer FO (1989). Combined liver and pancreas procurement with Belzer-UW solution. *Surgery*; 106: 685-691.
335. Stange BJ, Glanemann M, Nuessler NC, Settmacher U, Steinmuller T, Neuhaus P (2003). Hepatic artery thrombosis after adult liver transplantation. *Liver Transpl*; 9(6): 612-620.
336. Starzl TE, Marchioro TL, Von Kaulla KN, Hermann G, Brittain RS, Waddell WR (1963). Homotransplantation of the liver in humans. *Surg Gynecol Obstet*; 117: 559-576.
337. Starzl TE, Marchioro TL, Porter KA, Iwaki Y, Cerilli GJ (1967). The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. *Surg Gynecol Obstet*; 124: 301-318.

338. Starzl TE, Koep LJ, Schröter GPJ, Hood J, Halgrimson CG, Porter KA, Weil R (1979).
The quality of life after liver transplantation.
Transplant Proc; 11: 252-256.
339. Starzl TE, Klintmalm GBG, Porter KA, Iwatsuki S, Schroter GPJ (1981).
Liver transplantation with use of cyclosporine A and prednisone.
New Engl J Med; 303: 266-269.
340. Starzl TE, Iwatsuki S, van Thiel DH, Grtner JC, Zitelli BJ, Malatack J, Schade RR, Shaw BW, Hakala TR, Rosenthal T, Porter KA (1982).
Evolution of liver transplantation.
Hepatology; 2: 614-636.
341. Starzl TE (1984).
A flexible procedure for multiple cadaveric organ procurement.
Surg Gynecol Obstet; 165: 223-230.
342. Starzl TE (1989).
Late complications with gallbladder conduit biliary reconstruction after liver transplantation.
Transplantation; 48(3): 537-539.
343. Starzl TE, Demetris AJ, van Thiel D (1989).
Liver transplantation (first and second part).
N Engl J Med; 312: 1014-1022 and 1092-1099.
344. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataraman R, Jain A (1989).
FK506 for liver, kidney, and pancreas transplantation.
Lancet; 2: 1000-1004.
345. Starzl (1993).
FK506 versus Cyclosporine.
Transplant Proc; 25(1): 511-512.
346. Stein DP, Lederman RJ, Vogt DP, Carey WD, Broughan TA (1992).
Neurological complications following liver transplantation.
Ann Neurol; 31(6): 644-649.
347. Steinmüller T (1997)
Auswirkungen der Lebertransplantation und Immunsuppression auf den Glukosestoffwechsel.
Habilitationsschrift, HU-Berlin, 1997.
348. Steinmüller T, Stockmann M, Bechstein WO, Settmacher U, Jonas S, Neuhaus P (2000).
Liver transplantation and diabetes mellitus.
Exp Clin Endocrinol Diabetes; 108(6): 401-405.
349. Stewart SF, Hudson M, Talbot T, Manas D, Day C (2001).
Mycophenolate mofetil monotherapy in liver transplantation.
Lancet; 357: 609-610.
350. Stratta RJ, Wood RP, Langnas AN, Hollins RR, Bruder KJ, Donovan JP, Burnett DA, Lieberman RP, Lund GB, Pillen TJ, Markins RS, Shaw BW (1989).
Diagnosis and treatment of biliary tract complications after orthotopic liver transplantation.
Surgery; 106: 675-684.
351. Sugawara Y, Makuuchi M, Kaneko J, Kishi Y, Hata S, Kokuda N (2003).
Positive T lymphocytotoxic cross-match in living donor liver transplantation.
Liver Transpl; 9(10): 1062-1066.

352. Sylvestre PB, Batts KP, Burgart LJ, Poterucha JJ, Wiesner RH (2003).
Recurrence of primary biliary cirrhosis after liver transplantation: Histologic estimate of incidence and natural history.
Liver Transpl; 9(10): 1086-1093.
353. Taler SJ, Textor SC, Canzanello VJ, Schwartz L, Porayko M, Wiesner RH, Krom RA (1996).
Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine.
Transplantation; 62(11): 1588-1592.
354. Taler SJ, Textor SC, Canzanello VJ, Schwartz L (1999).
Cyclosporin-induced hypertension: incidence, pathogenesis and management.
Drug Saf; 20(5): 437-449.
355. Tarter RE, Switala JA, Arria A, Plail J, van Thiel D (1991).
Quality of life before and after orthotopic hepatic transplantation.
Arch Intern Med; 151: 1521-1526.
356. Taylor AL, Gibbs P, Bradley JA (2004).
Acute graft versus host disease following liver transplantation: the enemy within.
Am J Transplant; 4(4): 466-474.
357. Terrault NA (2002).
Treatment of recurrent hepatitis B infection in liver transplant recipients.
Liver Transpl; 8(10), Suppl. 1: S74-S81.
358. Textor SC, Canzanello VJ, Taler SJ, Schwartz L, Augustine J (1995).
Hypertension after liver transplantation.
Liver Transpl Surg; 1(5 Suppl 1): 20-28.
359. Textor SC, Taler SJ, Canzanello VJ, Schwartz L, Augustine JE (2000).
Posttransplantation hypertension related to calcineurin inhibitors.
Liver Transplant; 6(5): 521-530.
360. The US Multicenter FK506 Liver Study Group (1994).
A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation.
N Engl J Med; 331: 1110-1117.
361. Todo S, Tzakis A, Starzl TE (1988).
Preservation of livers with UW or Euro-Collins solution.
Transplantation; 46(6): 925-926.
362. Todo S, Nery J, Yanaga K, Podesta L, Gordon RD, Starzl TE (1989).
Extended preservation of human liver grafts with UW solution.
JAMA; 261: 711-714.
363. Trotter JF (2000).
Selection of donors and recipients for living donor liver transplantation.
Liver Transpl; 6 Suppl: S52-S56.
364. Trotter JF (2003).
Sirolimus in liver transplantation. Review.
Transplant Proc; 35 (Suppl 3): S193-S200.

365. Troidl H (1989).
Lebensqualität: ein relevantes Zielkriterium in der Chirurgie.
Chirurg; 60: 445-449.
366. Turgeon N, Hovingh GK, Fishman JA, Basgoz N, Tolckoff-Rubin NE, Doran M, Cosimi AB, Rubin RH (2000).
Safety and efficacy of granulocyte colony stimulating factor in kidney and liver transplant recipient.
Transplant Infect Dis; 2: 15-21.
367. Urbani L, Catalano G, Biancofiori G, Bindi L, Consani G, Bisa M, Boldrini A, Campatelli A (2003).
Surgical complications after liver transplantation.
Minerva Chir; 58(5): 675-692.
368. Ulm K (1997).
Studientypen, Statistik und Beurteilung der Ergebnisse.
In: Seelos HJ (Hrsg.): Medizinische Informatik, Biometrie und Epidemiologie.
Berlin, Walter deGruyter-Verlag: 281-295.
369. Valente JF, Alonso MH, Weber FL, Hanto DW (1996).
Late hepatic artery thrombosis in liver allograft recipients is associated with intrahepatic biliary necrosis.
Transplantation; 61(1): 61-65.
370. Villacian JS, Paya CV (1999).
Prevention of infections in solid organ transplant recipients.
Transpl Infect Dis; 1: 50-64.
371. Villamil FG (2002).
Hepatitis B: progress in the last 15 years.
Liver Transpl; 8(10), Suppl 1: S59-S66.
372. Vogel A, Heinrich E, Bahr MJ, Rifai K, Flemming P, Melter M, Klempnauer J, Nashan B, Manns MP, Strassburg CP (2004).
Long-term outcome of liver transplantation for autoimmune hepatitis.
Clin Transplant; 18: 62-69.
373. Vogl TJ, Pegios W, Balzer JO, Lobo M, Neuhaus P (2001).
Arterial steal syndrom in patients after liver transplantation: transarterial embolization of the splenic and gastroduodenal arteries.
Rofo Fortschr Geb Rontgenstr Neuen BildgebVerfahr; 173(10): 908-913.
374. Walter M, Scholler G, Moyzes D, Hildebrandt M, Neuhaus R, Danzer G, Klapp BF (2002).
Psychosocial prediction of abstinence from ethanol in alcoholic recipients following liver transplantation.
Transplant Proc; 34: 1239-1241.
375. Wang ZF, Liu C (2004).
Liver retransplantation: indications and outcomes.
Hepatobiliary Pancreat Dis Int; 3(2): 175-178.
376. Weinstein RS (2001).
Glucocorticoid-induced osteoporosis.
Endocr Metab Disord; 2: 65-73.

377. Welch CS (1955).
A note on transplantation of the whole liver in dogs.
Transplant Bull; 2: 54-55.
378. Wiesner RH, Hermans P, Rakela J, Washington JA 2nd, Perkins JD, DiCecco S, Krom R (1988).
Selective bowel decontamination to decrease gram-negative aerobic bacterial and *Candida* colonization and prevent infection after orthotopic liver transplantation.
Transplantation; 45(3): 570-574.
379. Wiesner RH, Lombardero M, Lake JR, Everhart J, Detre KM (1997).
Liver transplantation for end-stage alcoholic liver disease: an assessment of outcomes.
Liver Transpl Surg; 3(3): 231-239.
380. Wiesner RH, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, McMaster P, Kalayoglu M, Levy G, Freeman R, Bismuth H, Neuhaus P, Mamelok R, Wang W (2001).
A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients.
Liver Transpl; 7(5): 442-450.
381. Wiesner RH, Sorrell M, Villamil F (2003).
Report of the first international liver transplantation society expert panel consensus conference on liver transplantation and hepatitis C.
Liver Transpl; 9(11): 1-9.
382. Williams JW, Foster PF, Sankary HN (1992).
Role of liver allograft biopsy in patient management.
Semin Liver Dis; 12(1): 60-72. Review.
383. Winkler M, Niesert S, Ringe B (1992).
Successful pregnancy in a patient after liver transplantation maintained on FK506.
Transplantation; 56(6): 1589-1590.
384. Winkler M, Ringe B, Jost U, Melter M, Rodeck B, Buhr T, Brinkmann T, Pichlmayr R (1993).
Conversion from cyclosporin to FK506 after liver transplantation.
Transpl Int; 6: 319-324.
385. Winston DJ, Busuttill RW (2002).
Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients.
Transplantation; 74(5): 688-695.
386. Wonigeit K (1996).
Immunsuppression bei Organtransplantation.
Internist; 37(3): 3-13.
387. Wong F, Blendis L (2001).
New challenge of hepatorenal syndrome: prevention and treatment.
Hepatology; 34: 1242-1251.
388. Wood K (ed.) (1995).
The handbook of transplant immunology.
Med Sci Publications, Stokes Pages, Bucks, United Kingdom.
389. Xiol X, Guardiola J, Menendez S, Lama C, Figueras J, Marcoval J, Serrano T, Botargues JM, Maner M, Rota R (2001).

- Risk factors for development of de novo neoplasia after liver transplantation.
Liver Transpl; 7(11): 971-975.
390. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM (2001).
Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.
Hepatology; 34: 411-416.
391. Yao FY, Saab S, Bass NM, Hirose R, Ly D, Terrault N, Lazar NA, Bacchetti P, Ascher NL, Roberts JP (2004).
Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores.
Hepatology; 39: 230-238.
392. Yersiz H, Renz JF, Hisatake GM, Farmer DG, Busuttil RW (2003).
The conventional technique in in-situ split-liver transplantation.
J Hepatobiliary Pancreat Surg; 10(1): 11-15.
393. Yoo HY, Thuluvath PJ (2002).
The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation.
Transplantation; 74(7): 1007-1012.
394. Yoo HY, Maheshwari A, Thuluvath PJ (2003).
Retransplantation of liver: primary graft nonfunction and hepatitis C virus are associated with worse outcome.
Liver Transpl; 9(9): 897-904.
395. Zheng SS, Yu ZY, Liang TB, Wang WL, Shen Y, Zhang M, Xu X, Wu J (2004).
Prevention and treatment of hepatic artery thrombosis after liver transplantation.
Hepatobiliary Pancreat Dis Int; 3(1): 21-25.
396. Zwaveling JH, Maring JK, Klompmaaker IJ, Haagsma EB, Bottema JT, Laseur M, Winter HL, van Enkevort PJ, TenVergert EM, Metselaar HJ, Bruining HA, Slooff MJ (2002).
Selective decontamination of the digestive tract to prevent postoperative infection: a randomized placebo-controlled trial in liver transplant patients.
Crit Care Med; 30(6): 1204-1209.